Source comparison
Tesamorelin vs Other Peptides: Clearance Comparison
Tesamorelin 26–38 minutes 2–3 hours 24–72 hours (IGF-1 elevation) GHRH receptor agonist. Stimulates endogenous GH release Sermorelin 8–12 minutes 1–1.5 hours 12–24 hours (IGF-1 elevation) GHRH analogue. Shorter half-life, less stable than tesamorelin Ipamoreli
This comparison does not assign a generated winner or score.
- Tesamorelin
- 26–38 minutes
- 2–3 hours
- 24–72 hours (IGF-1 elevation)
- GHRH receptor agonist. Stimulates endogenous GH release
- Sermorelin
- 8–12 minutes
- 1–1.5 hours
- 12–24 hours (IGF-1 elevation)
- GHRH analogue. Shorter half-life, less stable than tesamorelin
- Ipamorelin
- 2 hours
- 8–10 hours
- 6–12 hours (GH pulse only)
- Ghrelin receptor agonist. No sustained IGF-1 elevation
- CJC-1295 (DAC)
- 6–8 days
- 28–32 days
- Weeks (chronic GH/IGF-1 elevation)
- GHRH analogue with drug affinity complex. Extremely long-acting
- Professional Assessment
- Tesamorelin offers the best balance between rapid clearance (minimising systemic exposure) and sustained IGF-1 response. Unlike CJC-1295, it doesn't accumulate; unlike sermorelin, it's metabolically stable enough to produce consistent effects.
- Tesamorelin's trans-3-hexenoic modification increases binding affinity at the GHRH receptor while remaining susceptible to rapid peptidase degradation. This design prevents accumulation. A critical safety feature. CJC-1295 with DAC, by contrast, resists enzymatic breakdown and lingers for weeks, raising safety concerns around prolonged GH elevation.
- Sermorelin clears even faster than tesamorelin but requires higher doses to achieve comparable IGF-1 responses because it lacks the hexenoic acid modification. Ipamorelin works through a different pathway entirely (ghrelin receptor agonism) and doesn't produce sustained IGF-1 elevation. It's useful for acute GH pulses but not for metabolic remodeling.
- For researchers comparing peptides for visceral fat reduction studies, our peptide collection includes research-grade tesamorelin synthesised with exact amino-acid sequencing and third-party purity verification. Critical when clearance kinetics and downstream effects are the primary endpoints.